# EDGAR Filing Document

**Accession Number:** 0001822359
**File Stem:** 0001822359-25-000060
**Filing Date:** 2025-6
**Character Count:** 6527
**Document Hash:** 6f2beee842ac037556708dd8354eba9a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001822359-25-000060.hdr.sgml**: 20250612

**ACCESSION NUMBER**: 0001822359-25-000060

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20250612

**ITEM INFORMATION**: Regulation FD Disclosure

**FILED AS OF DATE**: 20250612

**DATE AS OF CHANGE**: 20250612

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** DocGo Inc.
- **CENTRAL INDEX KEY:** 0001822359
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-HEALTH SERVICES [8000]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 852515483
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39618
- **FILM NUMBER:** 251043025

**BUSINESS ADDRESS:**
- **STREET 1:** 685 THIRD AVENUE
- **STREET 2:** 9TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** (844) 443-6246

**MAIL ADDRESS:**
- **STREET 1:** 685 THIRD AVENUE
- **STREET 2:** 9TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Motion Acquisition Corp.
- **DATE OF NAME CHANGE:** 20200824

?xml version='1.0' encoding='ASCII'? dcgo-20250612

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**___________________________________**

**FORM 8-K**

**___________________________________**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (date of earliest event reported): June 12, 2025**

**___________________________________**

**DOCGO INC.**

**(Exact name of registrant as specified in its charter)**

**___________________________________**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39618** | **85-2515483** |
| **(State or other jurisdiction of incorporation or organization)** | **(Commission File Number)** | |
| **685 Third Avenue, 9th Floor, New York, New York** | **685 Third Avenue, 9th Floor, New York, New York** | **(I.R.S. Employer Identification No.)**<br>**10017** |
| **(Address of principal executive offices)** | **(Address of principal executive offices)** | **(Zip Code)** |
| **(844) 443-6246** | **(844) 443-6246** | **(844) 443-6246** |
| **(Registrant's telephone number, including area code)** | **(Registrant's telephone number, including area code)** | **(Registrant's telephone number, including area code)** |
| **N/A** | **N/A** | **N/A** |
| **(Former name or former address, if changed since last report)** | **(Former name or former address, if changed since last report)** | **(Former name or former address, if changed since last report)** |

---

**___________________________________**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

| | | |
|:---|:---|:---|
| Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: | Securities registered pursuant to Section 12(b) of the Act: |
| **Title of each class** | **Trading Symbol** | **Name of each exchange on which registered** |
| **Common stock, par value $0.0001 per share** | **DCGO** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 12b-2 of the Exchange Act.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 7.01 Regulation FD Disclosure.**

On June 12, 2025, the Board of Directors of DocGo Inc. (the "Company") approved an extension of the expiration date of the Company's current share repurchase program ("Repurchase Program") from June 30, 2025 to December 31, 2025. As previously disclosed, pursuant to the Repurchase Program, the Company may purchase up to $26 million in shares of the Company's common stock. Other than the extension of the program's expiration date, no changes were made to the Repurchase Program.

Under the terms of the Repurchase Program, as extended, the Company may continue to purchase shares of its common stock on a discretionary basis from time to time through open market repurchases or privately negotiated transactions or through other means, including by entering into Rule 10b5-1 trading plans or accelerated share repurchase programs, in each case, during an "open window" and when the Company does not possess material non-public information.

The timing and actual number of shares repurchased under the Repurchase Program will depend on a variety of factors, including stock price, trading volume, market conditions, corporate and regulatory requirements and other general business considerations. The Repurchase Program may be modified, suspended or discontinued at any time without prior notice.

Repurchases under the Repurchase Program may be funded from the Company's existing cash and cash equivalents, future cash flow or proceeds of borrowings or debt offerings.

The information in Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed "filed" for purposes of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference to such filing.

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **DOCGO INC.** | **DOCGO INC.** |
| By: | /s/ Norman Rosenberg |
| Name: | Norman Rosenberg |
| Title: | Chief Financial Officer and Treasurer |

---

Date: June 12, 2025